普洛藥業(000739.SZ):上半年淨利潤6.25億元 同比增長3.96%
格隆匯8月15日丨普洛藥業(000739.SZ)公佈半年度報吿,報吿期內,公司實現營業收入64.29億元,同比增長7.96%;實現歸屬於上市公司股東的淨利潤6.25億元,同比增長3.96%;實現歸屬於上市公司股東的扣除非經常性損益的淨利潤6億元,同比增長1.24%。
2024年上半年,國際地緣政治依舊複雜、行業競爭依舊激烈,國內經濟復甦仍顯乏力、投融資環境仍然嚴峻,對公司經營和發展帶來了較大的壓力和挑戰;與此同時,全球醫藥行業規模持續增長、老齡化進程不斷加速、新技術的陸續湧現和行業政策持續優化,也為公司持續高質量發展提供了無限的機遇和空間。公司管理團隊始終對企業發展充滿信心,堅持長期主義、錨定發展目標,以為客户、為員工、為股東、為社會價值創造為使命,堅定實施深度國際化高質量發展戰略,堅持貫徹“強科技研發、高標準合規、低成本製造”發展理念,堅定不移地提升企業新質生產力,不斷增強企業核心競爭力,實現經營業績穩健增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.